Aller au contenu. | Aller à la navigation

Outils personnels

Navigation

Tutelles

logo Inserm      logo cnrslogo ENSL       logo ucb1


Tutelles secondaires

logo ENSL logo ucb1

Vous êtes ici : Accueil / Équipes / Lina B/Rosa-Calatrava M - VirPath / Publications / Recherche Clinique

Recherche Clinique

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non- human primates.

Prenafeta A, Bech-Sàbat G, Moros A, Barreiro A, Fernández A, Cañete M, Roca M, González-González L, Garriga C, Confais J, Toussenot M, Contamin H, Pizzorno A, Rosa-Calatrava M, Pradenas E, Marfil S, Blanco S, Cebollada Rica P, Sisteré-Oró M, Meyerhans A, Lorca C, Segalés J, Prat T, March R and Ferrer L.
Iscience 2023
https://doi.org/10.1016/j.isci.2023.107224

 

Antiviral Activity of Active Materials: Standard and Finger-Pad-Based Innovative Experimental Approaches.

Szpiro, L.; Bourgeay, C.; Hoareau, A.L.; Julien, T.; Menard, C.; Marie, Y.; Rosa-Calatrava, M.; Moules, V. Antiviral Activity of Active Materials: Standard and Finger-Pad-Based Innovative Experimental Approaches.
Materials 2023, 16, 2889.
https://doi.org/10.3390/ma16072889

 

Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19.

Hocini H, Wiedemann A, Blengio F, Lefebvre C, Cervantes-Gonzalez M, Foucat E, Tisserand P, Surenaud M, Coléon S, Prague M, Guillaumat L, Krief C, Fenwick C, Laouénan C, Bouadma L, Ghosn J, Pantaleo G, Thiébaut R; French COVID cohort study group; Lévy Y.J Clin Immunol. 2023 Mar 21:1–12.
doi: 10.1007/s10875-023-01459-x. Epub ahead of print. Erratum in: J Clin Immunol. 2023 Mar 30;: PMID: 36943669; PMCID: PMC10029801.

 

Oropharyngeal and intestinal concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adults.
Patrier J, Villageois-Tran K, Szychowiak P, Ruckly S, Gschwind R, Wicky PH, Gueye S, Armand-Lefevre L, Marzouk M, Sonneville R, Bouadma L, Petitjean M, Lamara F, de Montmollin E, Timsit JF, Ruppé E; French COVID Cohort Study Group.
Crit Care. 2022 Oct 3;26(1):300.
doi: 10.1186/s13054-022-04164-0. PMID: 36192756

 

Paediatric COVID-19 mortality: a database analysis of the impact of health resource disparity.
Marwali EM, Kekalih A, Yuliarto S, Wati DK, Rayhan M, Valerie IC, Cho HJ, Jassat W, Blumberg L, Masha M, Semple C, Swann OV, Kohns Vasconcelos M, Popielska J, Murthy S, Fowler RA, Guerguerian AM, Streinu-Cercel A, Pathmanathan MD, Rojek A, Kartsonaki C, Gonçalves BP, Citarella BW, Merson L, Olliaro PL, Dalton HJ; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Clinical Characterization Group Investigators.
BMJ Paediatr Open. 2022 Oct;6(1):e001657.
doi: 10.1136/bmjpo-2022-001657. PMID: 36645791

 

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study.
Reyes LF, Murthy S, Garcia‑Gallo E, Merson L, Ibáñez‑Prada E, Rello E, Fuentes Y, Martin‑Loeches I, Bozza F, Duque S,Taccone F, Fowler RA, Kartsonaki C, Gonçalves BP, Wanjiru Citarella B, Aryal D, Burhan E, Cummings MJ, Delmas C, Diaz R, Figueiredo‑Mello C, Hashmi M, Kumar Panda P, Jiménez M, Rincon D, Thomson D, Nichol A, Marshall JC, Olliaro P and the ISARIC Characterization Group.
Critical Care Sept 2022 26:276.

 

Differences in HADS and SF-36 scores 1 year after critical illness in COVID-19 patients.
Tallarico RT, Deniau B, Fong N, Ghosn J, Legrand M; French-COVID and the FROG-ICU Investigators.
Intensive Care Med. 2022 Sep;48(9):1245-1247.
doi: 10.1007/s00134-022-06797-9. Epub 2022 Jul 8. PMID: 35804201

 

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19.
ISARIC Clinical Characterization Group, Garcia-Gallo1 E, Merson L, Kennon K, Kelly S, Citarella B, Vidali Fryer D, Shrapnel S, Lee J, Duque S, Fuentes Y, Balan V, Smith S, Wei J, Gonçalves P, Russell C, Sigfrid L, Dagens A, Olliaro P, Baruch J, Kartsonaki C, Dunning J, Rojek A, Rashan A, Beane A, Murthy S, Reyes P. 
Scientific data 2022 Jul 30 2022; 9: 454.

 

 

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. ​

Matuozzo D, Talouarn E, et al., COVID Human Genetic Effort, COVIDeF Study Group, French COVID Cohort Study Group, CoV- Contact Cohort, COVID-STORM Clinicians, COVID Clinicians, Orchestra Working Group, Amsterdam UMC Covid-19 Biobank, NIAID-USUHS COVID Study Group, Meyts I, Zhang SY, Puel A, Notarangelo LD, Boisson-Dupuis S, Su HC, Boisson B, Jouanguy E, Casanova JL, Zhang Q, Abel L and Cobat A. 

July 2022 Accepted in Journal of Clinical Investigation

 

 

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs.
Bastard P, Vazquez S, Liu J, Laurie MT, Wang CY, Gervais A, Le Voyer T, Bizien L, Zamecnik C, Philippot Q, Rosain J, Catherinot E, Willmore A, Mitchell AM, Bair R, Garçon P, Kenney H, Fekkar A, Salagianni M, Poulakou G, Siouti E, Sahanic S, Tancevski I, Weiss G, Nagl L, Manry J, Duvlis S, Arroyo-Sánchez D, Paz Artal E, Rubio L, Perani C, Bezzi M, Sottini A, Quaresima V, Roussel L, Vinh DC, Reyes LF, Garzaro M, Hatipoglu N, Boutboul D, Tandjaoui-Lambiotte Y, Borghesi A, Aliberti A, Cassaniti I, Venet F, Monneret G, Halwani R, Sharif-Askari NS, Danielson J, Burrel S, Morbieu C, Stepanovskyy Y, Bondarenko A, Volokha A, Boyarchuk O, Gagro A, Neuville M, Neven B, Keles S, Hernu R, Bal A, Novelli A, Novelli G, Saker K, Ailioaie O, Antolí A, Jeziorski E, Rocamora-Blanch G, Teixeira C, Delaunay C, Lhuillier M, Le Turnier P, Zhang Y, Mahevas M, Pan-Hammarström Q, Abolhassani H, Bompoil T, Dorgham K; COVID HGE consortium †; French COVID study group †; COMET consortium †; Gorochov G, Laouenan C, Rodríguez-Gallego C, Ng LFP, Renia L, Pujol A, Belot A, Raffi F, Allende LM, Martinez-Picado J, Ozcelik T, Keles S, Imberti L, Notarangelo LD, Troya J, Solanich X, Zhang SY, Puel A, Wilson MR, Trouillet-Assant S, Abel L, Jouanguy E, Ye CJ, Cobat A, Thompson LM, Andreakos E, Zhang Q, Anderson MS, Casanova JL, DeRisi JL. 
Sci Immunol. 2022 Jun 14:eabp8966.
doi: 10.1126/sciimmunol.abp8966. Online ahead of print. PMID: 35857576

 

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Mégarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs CM, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari FS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Erikstrup C, Condino-Neto A, Prando C, Bondarenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James's Hospital, SARS CoV2 Interest Group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank Investigators; COVID Human Genetic Effort; CP-COVID-19 Group; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement Français du Sang Study group; Anderson MS, Boisson B, Béziat V, Zhang SY, Andreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, de Lamballerie X, Burdet C, Bouadma L, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Casanova JL, Abel L, Cobat A.
Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200413119.
doi: 10.1073/pnas.2200413119. Epub 2022 May 16. PMID: 35576468

 

Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers.
Saker K, Escuret V, Pitiot V, Massardier-Pilonchéry A, Paul S, Mokdad B, Langlois-Jacques C, Rabilloud M, Goncalves D, Fabien N, Guibert N, Fassier JB, Bal A, Trouillet-Assant S, Trabaud MA.
J Clin Microbiol. 2022 Jan 19;60(1):e0174621.
doi: 10.1128/JCM.01746-21. Epub 2021 Oct 27. PMID: 34705539

 

 

Chronic use of renin-angiotensin-aldosterone  system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review .
Gault N, Esposito-Farese M, Revest M, Inamo J, Cabie A, Polard E, Hulot JS, Ghosn J, Chirouze C, Deconinck L, French COVID Cohort Study Group. 

Fundamental & clinical pharmacology Dec 2021 Vol 35 issue 6 p1141-1158.

 

 

Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination.
Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, Peyrot L, Allatif O, Fassier JB, Massardier-Pilonchéry A, Brengel-Pesce K, Yaugel-Novoa M, Denolly S, Boson B, Bourlet T, Bal A, Valette M, Andrieu T, Lina B; Covid-Ser study group; Cosset FL, Paul S, Defrance T, Marvel J, Walzer T, Trouillet-Assant S. Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21. PMID: 34673755

 

 

 

Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort.
ISARIC Clinical Characterisation Group; Hall MD, Baruch J, Carson G, Citarella BW, Dagens A, Dankwa EA, Donnelly CA, Dunning J, Escher M, Kartsonaki C, Merson L, Pritchard M, Wei J, Horby PW, Rojek A, Olliaro
PL. Elife. 2021 Nov 23;10:e70970.
doi: 10.7554/eLife.70970. PMID: 34812731

 

 

COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study.

ISARIC Clinical Characterisation Group.

Infection Oct 2021 Vol 49 issue 5 p889-905

 

 

 

Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019.
Betton M, Livrozet M, Planas D, Fayol A, Monel B, Védie B, Bruel T, Tartour E, Robillard N, Manuguerra JC, Blanchard A, Ghosn J, Visseaux B, Péré H, Lebeaux D, Schwartz O, Veyer D, Hulot JS; French COVID Cohort Study Group.
Clin Infect Dis. 2021 Sep 15;73(6):e1337-e1344.
doi: 10.1093/cid/ciab308. PMID: 33851216

 

Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection.
Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, Mengin A, Gras A, Vidailhet P, Arnould-Michel R, Bibi-Triki S, Carapito R, Trouillet-Assant S, Perret M, Belot A, Bahram S, Arnaud L, Gottenberg JE, Fafi-Kremer S, Sibilia J.
Infect Dis Ther. 2021 Sep;10(3):1747-1763.
doi: 10.1007/s40121-021-00484-w. Epub 2021 Jul 10. PMID: 34245450

 

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.
Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, Zhang P, Meertens L, Bolze A, Materna M, Korniotis S, Gervais A, Talouarn E, Bigio B, Seeleuthner Y, Bilguvar K, Zhang Y, Neehus AL, Ogishi M, Pelham SJ, Le Voyer T, Rosain J, Philippot Q, Soler-Palacín P, Colobran R, Martin-Nalda A, Rivière JG, Tandjaoui-Lambiotte Y, Chaïbi K, Shahrooei M, Darazam IA, Olyaei NA, Mansouri D, Hatipoğlu N, Palabiyik F, Ozcelik T, Novelli G, Novelli A, Casari G, Aiuti A, Carrera P, Bondesan S, Barzaghi F, Rovere-Querini P, Tresoldi C, Franco JL, Rojas J, Reyes LF, Bustos IG, Arias AA, Morelle G, Christèle K, Troya J, Planas-Serra L, Schlüter A, Gut M, Pujol A, Allende LM, Rodriguez-Gallego C, Flores C, Cabrera-Marante O, Pleguezuelo DE, de Diego RP, Keles S, Aytekin G, Akcan OM, Bryceson YT, Bergman P, Brodin P, Smole D, Smith CIE, Norlin AC, Campbell TM, Covill LE, Hammarström L, Pan-Hammarström Q, Abolhassani H, Mane S, Marr N, Ata M, Al Ali F, Khan T, Spaan AN, Dalgard CL, Bonfanti P, Biondi A, Tubiana S, Burdet C, Nussbaum R, Kahn-Kirby A, Snow AL; COVID Human Genetic Effort; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-; Biobank; NIAID-USUHS COVID Study Group; Bustamante J, Puel A, Boisson-Dupuis S, Zhang SY, Béziat V, Lifton RP, Bastard P, Notarangelo LD, Abel L, Su HC, Jouanguy E, Amara A, Soumelis V, Cobat A, Zhang Q, Casanova JL.
Sci Immunol. 2021 Aug 19;6(62):eabl4348.
doi: 10.1126/sciimmunol.abl4348. PMID: 34413140

 

 

 

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari NS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Ostrowski SR, Condino-Neto A, Prando C, Bonradenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James's Hospital; SARS CoV2 Interest group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19; Biobank Investigators; COVID Human Genetic Effort; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement du Sang study group; Anderson MS, Boisson B, Béziat V, Zhang SY, Vandreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, de Lamballerie X, Duval X, Mentré F, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Cobat A, Abel L, Casanova JL.
Sci Immunol. 2021 Aug 19;6(62):eabl4340.
doi: 10.1126/sciimmunol.abl4340. PMID: 34413139

 

Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays.
Bal A, Trabaud MA, Fassier JB, Rabilloud M, Saker K, Langlois-Jacques C, Guibert N, Paul A, Alfaiate D, Massardier-Pilonchery A, Pitiot V, Morfin-Sherpa F, Lina B, Pozzetto B, Trouillet-Assant S; COVID SER Study Group.
Clin Microbiol Infect. 2021 Jun;27(6):933-935.
doi: 10.1016/j.cmi.2021.01.003. Epub 2021 Jan 13. PMID: 33450388

 

 

Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic. 

Baay M, Lina B*, Fontanet A, Marchant A, Saville M, Sabot P, Vandeputte J, Neels P.

Biologicals. 2020 Nov 19:S1045-1056(20)30137-8.  

 
 
 
 

Autoantibodies against type I IFNs in patients with life-threatening COVID-19. 

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group*; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL. 

Science. 2020 Oct 23;370(6515):eabd4585. 

 

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.

 

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y, Onodi F, Korniotis S, Karpf L, Philippot Q, Chbihi M, Bonnet-Madin L, Dorgham K, Smith N, Schneider WM, Razooky BS, Hoffmann HH, Michailidis E, Moens L, Han JE, Lorenzo L, Bizien L, Meade P, Neehus AL, Ugurbil AC, Corneau A, Kerner G, Zhang P, Rapaport F, Seeleuthner Y, Manry J, Masson C, Schmitt Y, Schlüter A, Le Voyer T, Khan T, Li J, Fellay J, Roussel L, Shahrooei M, Alosaimi MF, Mansouri D, Al-Saud H, Al-Mulla F, Almourfi F, Al-Muhsen SZ, Alsohime F, Al Turki S, Hasanato R, van de Beek D, Biondi A, Bettini LR, D'Angio' M, Bonfanti P, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Oler AJ, Tompkins MF, Alba C, Vandernoot I, Goffard JC, Smits G, Migeotte I, Haerynck F, Soler-Palacin P, Martin-Nalda A, Colobran R, Morange PE, Keles S, Çölkesen F, Ozcelik T, Yasar KK, Senoglu S, Karabela ŞN, Rodríguez-Gallego C, Novelli G, Hraiech S, Tandjaoui-Lambiotte Y, Duval X, Laouénan C; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group*; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort; NIAID-USUHS/TAGC COVID Immunity Group, Snow AL, Dalgard CL, Milner JD, Vinh DC, Mogensen TH, Marr N, Spaan AN, Boisson B, Boisson-Dupuis S, Bustamante J, Puel A, Ciancanelli MJ, Meyts I, Maniatis T, Soumelis V, Amara A, Nussenzweig M, García-Sastre A, Krammer F, Pujol A, Duffy D, Lifton RP, Zhang SY, Gorochov G, Béziat V, Jouanguy E, Sancho-Shimizu V, Rice CM, Abel L, Notarangelo LD, Cobat A, Su HC, Casanova JL. 

Science. 2020 Oct 23;370(6515):eabd4570.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Whole Genome Sequencing of A(H3N2) Influenza Viruses Reveals Variants Associated with Severity during the 2016–2017 Season.

Simon B, Pichon M, Valette M, Burfin G, Richard M, Lina B and Josset L.

Viruses. 2019 Jan 28, 11, 108; doi:10.3390/v11020108.

 

Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.

Pichon M, Picard C, Simon B, Gaymard A, Renard C, Massenavette B, Malcus C, Monneret G, Morfin-Sherpa F, Valette M, Javouhey E, Millat G, Lina B, Josset L, Escuret V.

Antiviral Res. 2018 Oct 11;160:1-9.

 

Cost and Burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France.

Kramer R, Duclos A,  the VRS study group in Lyon, Lina B, Casalegno JS.

Vaccine 2018, in press.

 

Molecular diversity and biennial circulation of enterovirus D68: a systematic screening study in Lyon, France, 2010 to 2016.

Kramer R, Sabatier M, Wirth T, Pichon M Lina B, Schuffenecker I, Josset L.

Euro Surveill. 2018 Sep ;23(37). doi: 10.2807/1560-7917.ES.2018.23.37.1700711.

 

The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections.

Ferraris O, Casalegno JS, Frobert E, Bouscambert Duchamp M, Valette M, Jacquot F, Raoul H, Lina B, Ottmann M.

Viruses. 2018 Sep 17;10(9). pii: E504. doi: 10.3390/v10090504.

 

Synergistic Effects of Influenza and Staphylococcus aureus Toxins on Inflammation Activation and Cytotoxicity in Human Monocytic Cell Lines.

Jeannoel M, Casalegno JS, Ottmann M, Badiou C, Dumitrescu O, Lina B, Lina G.

Toxins (Basel). 2018 Jul 11;10(7). pii: E286. doi: 10.3390/toxins10070286.

 

Impact of the Respiratory Microbiome on Host Responses to Respiratory Viral Infection

Pichon M, Lina B and Josset L.

Vaccines. 2017 Nov 3;5(4). pii: E40. doi: 10.3390/vaccines5040040. Review

 

Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.

Pichon M, Gaymard A, Josset L, Valette M, Millat G, Lina B, et al.  

Antiviral Res. 2017 Sep;145:160–7. doi: 10.1016/j.antiviral.2017.07.021

 

Early nasopharyngeal microbial signature associated with severe influenza in children: a retrospective pilot study.

Langevin S, Pichon M, Smith E, Morrison J, Bent Z, Green R, et al.  

J Gen Virol. 2017 Sep 8; doi: 10.1099/jgv.0.000920.

 

La balance HA-NA des virus influenza A (H1N1).

Le Briand N., Casalegno J.S., Escuret V., Gaymard A., Lina B., Ottmann M., Frobert E.

Virologie. 2016. doi : 10.1684/vir.2016.0628

 

Functional balance between Neuraminidase and Hemagglutinin in influenza viruses.

Gaymard A., Le Briand N., Frobert E., Lina B., Escuret V. 

Clinical Microbiology and Infection, 2016. doi: 10.1016/j.cmi.2016.07.007.

 

Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).

Gaymard A., Charles A., Sabatier M., Cortay J.C., Frobert E., Picard C., Casalegno J.S., Rosa-Calatrava M., Ferraris O., Valette M., Ottmann M., Lina B., Escuret V.

Journal of Antimicrobial Chemotherapy, 2016. DOI: 10.1093/jac/dkw275

 

Combining high-resolution contact data with virological data to investigate influenza transmission in a tertiary care hospital.

Voirin N, Payet C, Barrat A, Cattuto C, Khanafer N, Régis C, Kim BA, Comte B, Casalegno JS, Lina B, Vanhems P.

Infect Control Hosp Epidemiol. 2015 Mar;36(3):254-60. doi: 10.1017/ice.2014.53.

 

Clinical presentation of severe viral encephalitis with known causative agents in children: a retrospective study on 16 patients hospitalized in a pediatric intensive care unit (2008-2011).

Adenot M, Frobert E, Blanchard G, Morel B, Perrot L, Floret D, Javouhey E.

J Child Neurol. 2014 Nov;29(11):1508-18. doi: 10.1177/0883073813513330. Epub 2014 Jan 23.

 

[Pandemic potential of circulating avian influenza strains sharing common features with the 1918 influenza strain].

Lina B.

Med Sci (Paris). 2014 Oct;30(10):851-3. doi: 10.1051/medsci/20143010011. Epub 2014 Oct 14 [Article in French]

 

Functional balance between the hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 HA D222 variants.

Casalegno JS, Ferraris O, Escuret V, Bouscambert M, Bergeron C, Linès L, Excoffier T, Valette M, Frobert E, Pillet S, Pozzetto B, Lina B, Ottmann M.

PLoS One. 2014 Aug 13;9(8):e104009. doi: 10.1371/journal.pone.0104009. eCollection 2014.

 

A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses.

Escuret V, Collins PJ, Casalegno JS, Vachieri SG, Cattle N, Ferraris O, Sabatier M, Frobert E, Caro V, Skehel JJ, Gamblin S, Valla F, Valette M, Ottmann M, McCauley JW, Daniels RS, Lina B.

J Infect Dis. 2014 Oct 15;210(8):1260-9. doi: 10.1093/infdis/jiu244. Epub 2014 May 3.

 

Routes of transmission during a nosocomial influenza A(H3N2) outbreak among geriatric patients and healthcare workers.

Eibach D, Casalegno JS, Bouscambert M, Bénet T, Regis C, Comte B, Kim BA, Vanhems P, Lina B.

J Hosp Infect. 2014 Mar;86(3):188-93. doi: 10.1016/j.jhin.2013.11.009. Epub 2014 Jan 8.

 

Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections.

Ploin D, Chidiac C, Carrat F, Cohen B, Javouhey E, Mayaud C, Desenclos JC, Lina B, Leport C; Fluco study group.

J Clin Virol. 2013 Sep;58(1):114-9. doi: 10.1016/j.jcv.2013.05.025. Epub 2013 Jul 3.

 

[Description of patients with confirmed influenza A(H1N1)pdm09 admitted to an intensive care unit and identification of severity risk factors].

Payet C, Lutringer-Magnin D, Cassier P, Lina B, Argaud L, Allaouchiche B, Vanhems P.

Med Mal Infect. 2013 Feb;43(2):81-4. doi: 10.1016/j.medmal.2013.01.016. Epub 2013 Feb 28. [Article in French]

 

Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.

Pozo F1, Lina B, Andrade HR, Enouf V, Kossyvakis A, Broberg E, Daniels R, Lackenby A, Meijer A, Community Network of Reference Laboratories for Human Influenza in Europe.

J Clin Virol. 2013 May;57(1):5-12. doi: 10.1016/j.jcv.2013.01.009. Epub 2013 Jan 31.

 

Pandemic A(H1N1)2009 influenza vaccination in Lyon University Hospitals, France: perception and attitudes of hospital workers.

Valour F, Bénet T, Chidiac C; Study group.

Vaccine. 2013 Jan 11;31(4):592-5. doi: 10.1016/j.vaccine.2012.11.070. Epub 2012 Dec 7.

 

First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013.

Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, Campese C, Guéry B, Prouvost H, Lemaire X, Paty MC, Haeghebaert S, Antoine D, Ettahar N, Noel H, Behillil S, Hendricx S, Manuguerra JC, Enouf V, La Ruche G, Semaille C, Coignard B, Lévy-Bruhl D, Weber F, Saura C, Che D; investigation team.

Euro Surveill. 2013 Jun 13;18(24). pii: 20502.

 

Fatal influenza A(H1N1)pdm09 encephalopathy in immunocompetent man.

Simon M, Hernu R, Cour M, Casalegno JS, Lina B, Argaud L.

Emerg Infect Dis. 2013 Jun;19(6):1005-7. doi: 10.3201/eid1906.130062.

 

Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.

Blanchon T, Mentré F, Charlois-Ou C, Dornic Q, Mosnier A, Bouscambert M, Carrat F, Duval X, Enouf V, Leport C; Bivir Study Group.

Clin Microbiol Infect. 2013 Feb;19(2):196-203. doi: 10.1111/j.1469-0691.2011.03751.x. Epub 2012 Jan 20.

 

Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS).

Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, Schutten M, Monto AS.

Clin Infect Dis. 2013 May;56(9):1197-205. doi: 10.1093/cid/cis1220. Epub 2013 Jan 10.

 

Epidemiological data of staphylococcal scalded skin syndrome in France from 1997 to 2007 and microbiological characteristics of Staphylococcus aureus associated strains.

Lamand V, Dauwalder O, Tristan A, Casalegno JS, Meugnier H, Bes M, Dumitrescu O, Croze M, Vandenesch F, Etienne J, Lina G.

Clin Microbiol Infect. 2012 Dec;18(12):E514-21. doi: 10.1111/1469-0691.12053. Epub 2012 Oct 19.

 

Rescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinity.

Richard M, Erny A, Caré B, Traversier A, Barthélémy M, Hay A, Lin YP, Ferraris O, Lina B.

PLoS One. 2012;7(5):e33880. doi: 10.1371/journal.pone.0033880. Epub 2012 May 1.

 

High risk HPV contamination of endocavity vaginal ultrasound probes: an underestimated route of nosocomial infection?

Casalegno JS, Le Bail Carval K, Eibach D, Valdeyron ML, Lamblin G, Jacquemoud H, Mellier G, Lina B, Gaucherand P, Mathevet P, Mekki Y.

PLoS One. 2012;7(10):e48137. doi: 10.1371/journal.pone.0048137. Epub 2012 Oct 24.

 

T inflammatory memory CD8 T cells participate to antiviral response and generate secondary memory cells with an advantage in XCL1 production.

Jubin V, Ventre E, Leverrier Y, Djebali S, Mayol K, Tomkowiak M, Mafille J, Teixeira M, Teoh DY, Lina B, Walzer T, Arpin C, Marvel J.

Immunol Res. 2012 Jun;52(3):284-93. doi: 10.1007/s12026-012-8340-4.

 

H1N1 influenza A virus neuraminidase modulates infectivity in mice.

Ferraris O, Escuret V, Bouscambert M, Casalegno JS, Jacquot F, Raoul H, Caro V, Valette M, Lina B, Ottmann M.

Antiviral Res. 2012 Mar;93(3):374-80. doi: 10.1016/j.antiviral.2012.01.008. Epub 2012 Feb 1.

 

Increased detection of Mycoplasma pneumoniae infection in children, Lyon, France, 2010 to 2011.

Eibach D, Casalegno JS, Escuret V, Billaud G, Mekki Y, Frobert E, Bouscambert-Duchamp M, Lina B, Morfin F.

Euro Surveill. 2012 Feb 23;17(8). pii: 20094.

 

Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.

Delangue J, Salez N, Ninove L, Kieffer A, Zandotti C, Seston M, Lina B, Nougairede A, Charrel R, Flahault A, de Lamballerie X.

Clin Microbiol Infect. 2012 Feb;18(2):177-83. doi: 10.1111/j.1469-0691.2011.03545.x. Epub 2011 Jun 2.

 

The community impact of the 2009 influenza pandemic in the WHO European region: a comparison with historical seasonal data from 28 countries.

Martirosyan L, Paget WJ, Jorgensen P, Brown CS, Meerhoff TJ, Pereyaslov D, Mott JA; EuroFlu group.

BMC Infect Dis. 2012 Feb 10;12:36. doi: 10.1186/1471-2334-12-36.

 

Influenza vaccination of healthcare workers in acute-care hospitals: a case-control study of its effect on hospital-acquired influenza among patients.

Bénet T1, Régis C, Voirin N, Robert O, Lina B, Cronenberger S, Comte B, Coppéré B, Vanhems P.

BMC Infect Dis. 2012 Feb 1;12:30. doi: 10.1186/1471-2334-12-30.

 

Influenza vaccine effectiveness among adult patients in a University of Lyon hospital (2004-2009).

Amour S, Voirin N, Regis C, Bouscambert-Duchamp M, Comte B, Coppéré B, Pires-Cronenberger S, Lina B, Vanhems P.

Vaccine. 2012 Jan 20;30(5):821-4. doi: 10.1016/j.vaccine.2011.11.033. Epub 2011 Dec 2.

 

Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France.

Bone A, Guthmann JP, Assal A, Rousset D, Degeorges A, Morel P, Valette M, Enouf V, Jacquot E, Pelletier B, Le Strat Y, Pillonel J, Fonteneau L, van der Werf S, Lina B, Tiberghien P, Lévy-Bruhl D.

PLoS One. 2012;7(3):e33056. doi: 10.1371/journal.pone.0033056. Epub 2012 Mar 22.

 
 

Vaccination coverage with seasonal and pandemic influenza vaccines in children in France, 2009-2010 season.

Weil-Olivier C, Lina B.

Vaccine. 2011 Sep 16;29(40):7075-9. doi: 10.1016/j.vaccine.2011.07.018. Epub 2011 Jul 21.

 

Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients.

Cotte L, Voirin N, Richard C, Brochier C, Schlienger I, Lack P, Lina B, Vanhems P, Zoulim F.

Vaccine. 2011 Aug 5;29(34):5638-44. doi: 10.1016/j.vaccine.2011.06.013. Epub 2011 Jun 23.

 

Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.

Richard M, Ferraris O, Erny A, Barthélémy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B.

Antimicrob Agents Chemother. 2011 Jun;55(6):2942-52. doi: 10.1128/AAC.01699-10. Epub 2011 Mar 21.

 

Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France.

Pelat C, Falchi A, Carrat F, Mosnier A, Bonmarin I, Turbelin C, Vaux S, van der Werf S, Cohen JM, Lina B, Blanchon T, Hanslik T.

PLoS One. 2011 May 10;6(5):e19621. doi: 10.1371/journal.pone.0019621.

 

Risk of influenza-like illness in an acute health care setting during community influenza epidemics in 2004-2005, 2005-2006, and 2006-2007: a prospective study.

Vanhems P, Voirin N, Roche S, Escuret V, Regis C, Gorain C, Pires-Cronenberger S, Giard M, Lina B, Najioullah F, Barret B, Pollissard L, David S, Crozet MN, Comte B, Hirschel B, Ecochard R.

Arch Intern Med. 2011 Jan 24;171(2):151-7. doi: 10.1001/archinternmed.2010.500.

 

Beyond the influenza-like illness surveillance: The need for real-time virological data.

Casalegno JS, Frobert E, Escuret V, Bouscambert-Duchamp M, Billaud G, Mekki Y, Schuffenecker I, Lina B, Morfin F, Valette M.

Euro Surveill. 2011 Jan 6;16(1). pii: 19756.

 

Factors influencing uptake of influenza vaccine amongst healthcare workers in a regional center after the A(H1N1) 2009 pandemic: lessons for improving vaccination rates.

Tagajdid MR, El Annaz H, Belefquih B, Doblali T, Casalegno JS, Mekki Y, Mrani S.

Int J Risk Saf Med. 2011;23(4):249-54. doi: 10.3233/JRS-2011-0544.

 

High-resolution measurements of face-to-face contact patterns in a primary school.

Stehlé J, Voirin N, Barrat A, Cattuto C, Isella L, Pinton JF, Quaggiotto M, Van den Broeck W, Régis C, Lina B, Vanhems P.

PLoS One. 2011;6(8):e23176. doi: 10.1371/journal.pone.0023176. Epub 2011 Aug 16.

 

[Necrotizing community-acquired pneumonia secondary to influenza a (H1N1) super-infected by an invasive group A streptococcus].

Casalegno JS, Escuret V, Celard M, Bouscambert M, Frobert E, Mekki Y, Lina G, Lina B.

Med Mal Infect. 2010 Dec;40(12):710-2. doi: 10.1016/j.medmal.2010.02.003. Epub 2010 Apr 18.[Article in French]

 

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.

Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentré F, Leport C; Bivir Study Group.

PLoS Med. 2010 Nov 2;7(11):e1000362. doi: 10.1371/journal.pmed.1000362.

 

Genetic content of Influenza H3N2 vaccine seeds.

Bergeron C, Valette M, Lina B, Ottmann M.

PLoS Curr. 2010 Sep 5;2:RRN1165.

 

Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009.

Casalegno JS, Bouscambert-Duchamp M, Caro V, Schuffenecker I, Sabatier M, Traversier A, Valette M, Lina B, Ferraris O, Escuret V.

Antiviral Res. 2010 Aug;87(2):242-8.

 

Anti N1 cross-protecting antibodies against H5N1 detected in H1N1 infected people.

Frobert E, Bouscambert-Duchamp M, Escuret V, Mundweiler S, Barthélémy M, Morfin F, Valette M, Gerdil C, Lina B, Ferraris O.

Curr Microbiol. 2010 Jul;61(1):25-8. doi: 10.1007/s00284-009-9571-z. Epub 2009 Dec 25.

 

Rhinoviruses delayed the circulation of the pandemic influenza A (H1N1) 2009 virus in France.

Casalegno JS, Ottmann M, Duchamp MB, Escuret V, Billaud G, Frobert E, Morfin F, Lina B.

Clin Microbiol Infect. 2010 Apr;16(4):326-9. doi: 10.1111/j.1469-0691.2010.03167.x. Epub 2010 Jan 28.

 

[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F.

Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19. [Article in French]

 

Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful?

Duchamp MB, Casalegno JS, Gillet Y, Frobert E, Bernard E, Escuret V, Billaud G, Valette M, Javouhey E, Lina B, Floret D, Morfin F.

Clin Microbiol Infect. 2010 Apr;16(4):317-21. doi: 10.1111/j.1469-0691.2010.03169.x. Epub 2010 Jan 28.

 

Impact of the 2009 influenza A(H1N1) pandemic wave on the pattern of hibernal respiratory virus epidemics, France, 2009.

Casalegno JS, Ottmann M, Bouscambert-Duchamp M, Valette M, Morfin F, Lina B.

Euro Surveill. 2010 Feb 11;15(6). pii: 19485.

 

Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance.

Ottmann M, Duchamp MB, Casalegno JS, Frobert E, Moulès V, Ferraris O, Valette M, Escuret V, Lina B.

Antivir Ther. 2010;15(5):721-6. doi: 10.3851/IMP1576.